CD274 and cancer: Certain micropeptides derived from ncRNAs can counteract the immune evasion strategies employed by cancer cells; for example, the LISRR ncRNA suppresses the production of neoantigens while promoting the translation of PD-L1—a key player in immune checkpoint pathways.